The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

Total Raised




About Aragon Pharmaceuticals

Aragon Pharmaceuticals is a small-molecule drug discovery company focused on developing medicines for the treatment of hormonally-driven cancers. These cancers eventually become resistant to existing 1st generation antihormonal therapies, and follow-up treatments are largely ineffective or toxic. The company's lead compound, ARN-509, is an antiandrogen undergoing a Phase I/II clinical trial in patients with progressive, advanced castration-resistant prostate cancer. In addition to ARN-509, Aragon is advancing several compounds designed to both block and destroy hormone receptors that drive tumor growth. These agents should be effective in all stages of endocrine driven tumors including prostate and breast cancer and have potential in treating endometrial and ovarian cancer. The agents offer an opportunity to be superior to 1st generation anti-hormonal agents and therefore provide the opportunity for Aragon to expand its pipeline to early stage disease.In August 2013, Aragon Pharmaceuticals was acquired by Johnson & Johnson. The valuation of Aragon Pharmaceuticals was $650 million. Other terms of the deal were not released.

Aragon Pharmaceuticals Headquarter Location

12780 El Camino Real Suite 301

San Diego, California, 92130,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aragon Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aragon Pharmaceuticals is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Aragon Pharmaceuticals Patents

Aragon Pharmaceuticals has filed 36 patents.

The 3 most popular patent topics include:

  • Antiandrogens
  • Androgens and anabolic steroids
  • Androstanes
patents chart

Application Date

Grant Date


Related Topics




Antiandrogens, Experimental cancer drugs, Hormonal antineoplastic drugs, Trifluoromethyl compounds, Syndromes


Application Date


Grant Date



Related Topics

Antiandrogens, Experimental cancer drugs, Hormonal antineoplastic drugs, Trifluoromethyl compounds, Syndromes



Latest Aragon Pharmaceuticals News

Frazier Life Sciences Adds Highly Experienced Biopharmaceutical Executive to Team

Feb 22, 2022

February 22, 2022 08:00 AM Eastern Standard Time MENLO PARK, Calif.--( BUSINESS WIRE )--Frazier Life Sciences announced the addition of Angie You, Ph.D. as a Senior Advisor. She most recently served as Chief Executive Officer of Amunix Pharmaceuticals Inc. until its acquisition by Sanofi for up to $1.225 billion. Prior to joining Amunix, Dr. You served as Chief Business & Strategy Officer and Head of Commercial at Sierra Oncology (NASDAQ: SRRA), a publicly listed hematology and oncology drug development company, where she helped the company through a successful initial public offering. She also led the company’s strategic and transactional business and commercial efforts, including building its robust pipeline through acquisition and licensing of several product assets. Prior to Sierra, Dr. You served as Chief Business Officer of Aragon Pharmaceuticals, a private oncology drug discovery and development company, where she was responsible for finance, operations, human resources, and business development. At Aragon, she helped secure several rounds of financing as well as leading the business development process that resulted in the company’s acquisition by Johnson & Johnson. In previous roles, Dr. You served as Chief Business Officer at Synosia Therapeutics and Ren Pharmaceuticals. Before joining Ren Pharmaceuticals, she focused on new company formation at Venrock Ventures. Dr. You earned a Ph.D. in Biochemistry from Harvard University and a B.A. in Chemistry from Harvard College. “We are excited about being able to continue to work with Angie after the sale of Amunix,” said Managing Partner Jamie Topper. “She is a highly experienced biopharmaceutical executive who will help us identify and evaluate investment opportunities.” About Frazier Life Sciences Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences funds comprise over $2.1 billion in capital raised (as of January 2022), including venture funds focusing on company creation and private companies, and a public fund focused on small and mid-cap public companies. Since 2005, 61 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Menlo Park, California (headquarters), San Diego, Seattle, Boston, New York, and London. For more information about Frazier Life Sciences, please visit . Contacts

  • When was Aragon Pharmaceuticals founded?

    Aragon Pharmaceuticals was founded in 2009.

  • Where is Aragon Pharmaceuticals's headquarters?

    Aragon Pharmaceuticals's headquarters is located at 12780 El Camino Real, San Diego.

  • What is Aragon Pharmaceuticals's latest funding round?

    Aragon Pharmaceuticals's latest funding round is Acquired.

  • How much did Aragon Pharmaceuticals raise?

    Aragon Pharmaceuticals raised a total of $122M.

  • Who are the investors of Aragon Pharmaceuticals?

    Investors of Aragon Pharmaceuticals include Johnson & Johnson, OrbiMed Advisors, The Column Group, Aisling Capital, Topspin Consumer Partners and 3 more.

  • Who are Aragon Pharmaceuticals's competitors?

    Competitors of Aragon Pharmaceuticals include Tetraphase Pharmaceuticals, Biovertis, Acetylon Pharmaceuticals, Syndax Pharmaceuticals, Auspex Pharmaceuticals and 12 more.

You May Also Like

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

Metronome Therapeutics

Metronome Therapeutics is developing oncology drugs

AnaMar Medical

AnaMar Medical is a company in the field of cartilage biology and associated joint diseases. The company has an project portfolio with five drugs and one biomarker in development and two biomarkers on the market.

Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

Locus Pharmaceuticals

Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing small molecule therapeutic drugs to address unmet medical needs. The company's core technology is a fragment-based, computational approach, which Locus has combinated with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform.


MuriGen is building a portfolio of drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.